section name header

Basics

[Show Section Outline]

DESCRIPTION

Gold compounds are anti-inflammatory medications used orally and parenterally in the treatment of rheumatoid arthritis.

FORMS AND USES

Therapeutic forms of gold include auranofin (Ridaura), gold thiopolypeptide (GTPP), gold sodium thioglucose (Solganal), gold sodium thiomalate (Myochrysine), gold thiosulfate (Sanocrysin), and gold thioglycanide.

TOXIC DOSE

For unknown reasons, there is little correlation between the cumulative dose of a gold compound and clinical toxicity.

PATHOPHYSIOLOGY

EPIDEMIOLOGY

Poisoning is uncommon.

CAUSES

PREGNANCY AND LACTATION

US FDA Pregnancy Category C. The drug exerts animal teratogenic or embryocidal effects, but there are no controlled studies in women, or no studies are available in animals or women.


Section Outline:

Diagnosis

[Show Section Outline]

DIFFERENTIAL DIAGNOSIS

Other causes of mucous membrane inflammation include colchicine and several antineoplastic drugs.

SIGNS AND SYMPTOMS

HEENT

Dermatologic

Cardiovascular

Pulmonary

Interstitial pneumonitis and fibrosis have occurred during chronic use.

Gastrointestinal

Diarrhea, enteritis, and colitis are common effects.

Hepatic

Hepatitis and cholestasis develop rarely.

Renal

Hematologic

Neurologic

Toxicity occurs rarely and includes Guillain-Barré syndrome, encephalopathy, and stroke.

PROCEDURES AND LABORATORY TESTS

Essential Tests

Complete blood count and urinalysis should be obtained throughout therapy to evaluate hematopoietic effects of exposure.

Recommended Tests

Not Recommended Tests

Serum levels of gold are highly variable and do not correlate well with toxic reactions.


Section Outline:

Treatment

[Show Section Outline]

DIRECTING PATIENT COURSE

The health-care professional should call the poison control center when:

The patient should be referred to a health-care facility when:

Admission Considerations

Patients with acute toxicity, or those with chronic toxicity causing clinically significant bone marrow depression, should be admitted.

DECONTAMINATION

Out of Hospital

Emesis should be induced with ipecac within 1 hour of ingestion for either pediatric or adult patients, if health-care evaluation will be delayed.

In Hospital

ANTIDOTES

Chelation can be achieved with the following substances, which all require 10 to 14 days of therapy. See individual chapters for further details of chelator administration.

ADJUNCTIVE TREATMENT


Section Outline:

FollowUp

[Show Section Outline]

PATIENT MONITORING

Serial laboratory studies should be obtained to confirm reversal of toxicity.

EXPECTED COURSE AND PROGNOSIS

DISCHARGE CRITERIA/INSTRUCTIONS

Patients may be discharged from the emergency department or hospital when toxic effects resolve or stabilize and after psychiatric evaluation, if needed.


Section Outline:

Pitfalls

TREATMENT

Miscellaneous

ICD-9-CM 961.2

Poisoning by antiinfectives: heavy metal antiinfectives.

See Also: SECTION III, British Antilewisite and penicillamine chapters.

RECOMMENDED READING

Felson DT, et al. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis; results of two metaanalyses. Arthritis Rheum 1990;33:1449-1461.

Schumacher HR, ed. Primer on the rheumatic diseases, 9th ed. Atlanta: The Arthritis Foundation, 1995.

Author: John P. Marshall

Reviewer: Richard C. Dart